Investigating how T-cells contribute to heart failure
Comparing the role of MyD88 and TRIF in T-cell effector function and the development of heart failure
This study is looking at how certain proteins in your immune system affect heart function and inflammation, with the hope of finding new ways to help people with heart failure feel better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10912027 on NIH RePORTER |
What this research studies
This research aims to understand the mechanisms by which T-cells are activated and how they contribute to heart failure, a serious condition characterized by heart dysfunction and inflammation. The study focuses on two key proteins, MyD88 and TRIF, which play roles in T-cell signaling and activation. By examining how these proteins affect T-cell behavior in the heart, the research seeks to uncover new pathways that could lead to better treatments for heart failure. Patients with heart failure may benefit from insights gained into the inflammatory processes that exacerbate their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure who may be experiencing inflammation-related complications.
Not a fit: Patients without heart failure or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that target T-cell activation to improve heart failure outcomes.
How similar studies have performed: While the specific focus on T-cell bystander activation in heart failure is relatively novel, similar studies have shown promise in understanding immune responses in other inflammatory conditions.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Bayer, Abraham — Tufts University Boston
- Study coordinator: Bayer, Abraham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.